162 related articles for article (PubMed ID: 17433186)
1. [Pseudomonas aeruginosa: combined treatment vs. monotherapy].
Bodí M; Garnacho J
Med Intensiva; 2007 Mar; 31(2):83-7. PubMed ID: 17433186
[TBL] [Abstract][Full Text] [Related]
2. Pseudomonas aeruginosa serious infections: mono or combination antimicrobial therapy?
Bassetti M; Righi E; Viscoli C
Curr Med Chem; 2008; 15(5):517-22. PubMed ID: 18289007
[TBL] [Abstract][Full Text] [Related]
3. Pseudomonas aeruginosa bloodstream infections: how should we treat them?
van Delden C
Int J Antimicrob Agents; 2007 Nov; 30 Suppl 1():S71-5. PubMed ID: 17698326
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial combination treatment including ciprofloxacin decreased the mortality rate of Pseudomonas aeruginosa bacteraemia: a retrospective cohort study.
Paulsson M; Granrot A; Ahl J; Tham J; Resman F; Riesbeck K; Månsson F
Eur J Clin Microbiol Infect Dis; 2017 Jul; 36(7):1187-1196. PubMed ID: 28110415
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia.
Chamot E; Boffi El Amari E; Rohner P; Van Delden C
Antimicrob Agents Chemother; 2003 Sep; 47(9):2756-64. PubMed ID: 12936970
[TBL] [Abstract][Full Text] [Related]
6. Monotherapy or combination therapy? The Pseudomonas aeruginosa conundrum.
Traugott KA; Echevarria K; Maxwell P; Green K; Lewis JS
Pharmacotherapy; 2011 Jun; 31(6):598-608. PubMed ID: 21923444
[TBL] [Abstract][Full Text] [Related]
7. Combination antibiotic therapy versus monotherapy for Pseudomonas aeruginosa bacteraemia: a meta-analysis of retrospective and prospective studies.
Hu Y; Li L; Li W; Xu H; He P; Yan X; Dai H
Int J Antimicrob Agents; 2013 Dec; 42(6):492-6. PubMed ID: 24139926
[TBL] [Abstract][Full Text] [Related]
8. β-Lactam plus aminoglycoside or fluoroquinolone combination versus β-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis.
Vardakas KZ; Tansarli GS; Bliziotis IA; Falagas ME
Int J Antimicrob Agents; 2013 Apr; 41(4):301-10. PubMed ID: 23410791
[TBL] [Abstract][Full Text] [Related]
9. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study.
Deal EN; Micek ST; Reichley RM; Ritchie DJ
Clin Ther; 2009 Feb; 31(2):299-310. PubMed ID: 19302902
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.
Kim HS; Park BK; Kim SK; Han SB; Lee JW; Lee DG; Chung NG; Cho B; Jeong DC; Kang JH
BMC Infect Dis; 2017 Jul; 17(1):500. PubMed ID: 28716109
[TBL] [Abstract][Full Text] [Related]
11. Active monotherapy and combination therapy for extensively drug-resistant Pseudomonas aeruginosa pneumonia.
Khawcharoenporn T; Chuncharunee A; Maluangnon C; Taweesakulvashra T; Tiamsak P
Int J Antimicrob Agents; 2018 Dec; 52(6):828-834. PubMed ID: 30236956
[TBL] [Abstract][Full Text] [Related]
12. Combinations of antibiotics against Pseudomonas aeruginosa.
Baltch AL; Smith RP
Am J Med; 1985 Jul; 79(1A):8-16. PubMed ID: 3927722
[TBL] [Abstract][Full Text] [Related]
13. [Pseudomonas aeruginosa bacteremia: associations with a source of infection and antibiotic resistance].
Dambrauskiene A; Adukauskiene D; Jeroch J; Vitkauskiene A
Medicina (Kaunas); 2009; 45(1):1-7. PubMed ID: 19223699
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia.
Bowers DR; Liew YX; Lye DC; Kwa AL; Hsu LY; Tam VH
Antimicrob Agents Chemother; 2013 Mar; 57(3):1270-4. PubMed ID: 23263001
[TBL] [Abstract][Full Text] [Related]
15. Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.
Sader HS; Huband MD; Castanheira M; Flamm RK
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069652
[No Abstract] [Full Text] [Related]
16. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
Lee CH; Su TY; Ye JJ; Hsu PC; Kuo AJ; Chia JH; Lee MH
J Microbiol Immunol Infect; 2017 Oct; 50(5):677-683. PubMed ID: 26188977
[TBL] [Abstract][Full Text] [Related]
17. Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia.
Morata L; Cobos-Trigueros N; Martínez JA; Soriano A; Almela M; Marco F; Sterzik H; Núñez R; Hernández C; Mensa J
Antimicrob Agents Chemother; 2012 Sep; 56(9):4833-7. PubMed ID: 22751533
[TBL] [Abstract][Full Text] [Related]
18. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment.
Micek ST; Lloyd AE; Ritchie DJ; Reichley RM; Fraser VJ; Kollef MH
Antimicrob Agents Chemother; 2005 Apr; 49(4):1306-11. PubMed ID: 15793102
[TBL] [Abstract][Full Text] [Related]
19. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
Waters V; Ratjen F
Cochrane Database Syst Rev; 2012 Nov; 11():CD009528. PubMed ID: 23152277
[TBL] [Abstract][Full Text] [Related]
20. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO
Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
